首页> 美国卫生研究院文献>other >A peptide-free liposome-based oligosaccharide vaccine adjuvanted with a natural killer T cell antigen generates robust antibody responses in vivo
【2h】

A peptide-free liposome-based oligosaccharide vaccine adjuvanted with a natural killer T cell antigen generates robust antibody responses in vivo

机译:一种无肽基于脂质体的寡糖疫苗辅以天然杀伤性T细胞抗原可在体内产生强大的抗体反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Due to the prevalence of oligo- and polysaccharides on the surfaces of pathogenic organisms, carbohydrates are primary targets for recognition by antibodies generated by the immune systems of higher organisms. Consequently, substantial effort has been expended in efforts to develop vaccines based on carbohydrate epitopes. Typical approaches involve multivalent presentation of carbohydrate targets on antigenic peptides or proteins, which often involve substantial synthetic commitments and/or vaccines that are heterogeneous and difficult to characterize. We have developed a simple, liposome-based approach to generate multivalent carbohydrate vaccines, and in place of an antigenic peptide or protein, we have used a potent antigen for natural killer T cells. This vaccine, based on the Streptococcus pneumoniae serotype 14 polysaccharide, gave a response superior to that from a clinically used vaccine (Prevnar). The dependence of this response on liposome formation was demonstrated by comparison to a simple mixture of the oligosaccharide and the natural killer T cell adjuvant. The importance of the strength of the adjuvant was observed by use of a potent synthetic adjuvant and a weaker, bacterial derived glycolipid adjuvant. These results demonstrate the effectiveness of this novel and relatively simple means of generating carbohydrate-based vaccines.
机译:由于病原生物表面上普遍存在寡糖和多糖,碳水化合物是高级生物免疫系统生成的抗体识别的主要目标。因此,在开发基于碳水化合物表位的疫苗方面已经花费了大量的精力。典型的方法涉及在抗原性肽或蛋白质上碳水化合物靶标的多价呈递,这通常涉及大量的合成承诺和/或异质且难以表征的疫苗。我们已经开发出一种简单的基于脂质体的方法来生产多价碳水化合物疫苗,并且已经使用一种有效的抗原代替天然的杀伤性T细胞来取代抗原性肽或蛋白质。这种疫苗以肺炎链球菌血清型14多糖为基础,其反应优于临床使用的疫苗(Prevnar)。通过与寡糖和天然杀伤性T细胞佐剂的简单混合物比较,证明了该反应对脂质体形成的依赖性。通过使用有效的合成佐剂和较弱的细菌衍生糖脂佐剂,可以观察到佐剂强度的重要性。这些结果证明了产生基于碳水化合物的疫苗的这种新颖且相对简单的方法的有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号